Partial
Partially Aligned
Patient Risk:
Moderate
Summary
Most claims about indications and increased bleeding risk with anticoagulants/antiplatelet agents are supported by the provided label text. One provided claim set contains a contradiction: pancreatitis risk reduction is contradicted because the label states the effect on pancreatitis risk has not been determined.
Category Scores
Accurate Statements
VASCEPA is indicated as an adjunct to maximally tolerated statin therapy to reduce the risk of myocardial infarction, stroke, coronary revascularization, and unstable angina requiring hospitalization in adult patients with elevated triglyceride (TG) levels (≥150 mg/dL) and established cardiovascular disease or diabetes with 2 or more additional risk factors.
Label 1 INDICATIONS AND USAGE: adjunct to maximally tolerated statin therapy; reduce risk of MI, stroke, coronary revascularization, and unstable angina requiring hospitalization; adult patients with TG ≥150 mg/dL and established cardiovascular disease or diabetes mellitus and 2 or more additional risk factors.
VASCEPA is indicated as an adjunct to diet to reduce TG levels in adult patients with severe (≥500 mg/dL) hypertriglyceridemia.
Label 1 INDICATIONS AND USAGE: adjunct to diet to reduce TG levels in adult patients with severe (≥500 mg/dL) hypertriglyceridemia.
Some omega-3 fatty acid studies show prolongation of bleeding time, without exceeding normal limits or producing clinically significant bleeding; patients should be monitored when VASCEPA is used with concomitant anticoagulants and/or antiplatelet agents.
Label 7 DRUG INTERACTIONS 7.1: prolongation of bleeding time not exceeding normal limits; did not produce clinically significant bleeding episodes; monitor patients receiving VASCEPA and concomitant anticoagulants and/or antiplatelet agents for bleeding.
VASCEPA is associated with an increased risk of bleeding, and the incidence of bleeding is greater with concomitant antithrombotic medications such as aspirin and warfarin (as well as clopidogrel).
Label 5 WARNINGS AND PRECAUTIONS 5.3 Bleeding: increased risk of bleeding; serious bleeding events; incidence greater with concomitant antithrombotic medications such as aspirin, clopidogrel, or warfarin.
Unsupported Statements
Taking Vascepa with warfarin may require monitoring INR levels closely and adjusting the warfarin dose as needed.
The provided label text does not mention INR monitoring or warfarin dose adjustment instructions.
Taking Vascepa with atorvastatin may increase the risk of muscle damage; taking Vascepa with simvastatin may increase the risk of muscle damage; monitoring muscle enzymes and adjusting the statin dose as needed.
The provided label text does not support statin/muscle-damage interaction claims or related monitoring/dose adjustment instructions.
Taking Vascepa with ibuprofen may increase the risk of bleeding; require monitoring bleeding time and adjusting ibuprofen dose as needed.
The provided label text does not mention ibuprofen, NSAIDs, bleeding-time monitoring, or dose adjustment for ibuprofen.
Taking Vascepa with naproxen may increase the risk of bleeding.
The provided label text does not mention naproxen or related bleeding interaction claims.
Taking Vascepa with cholestyramine may decrease Vascepa absorption; Vascepa should be taken at least 4 hours before or after cholestyramine.
The provided label text does not mention cholestyramine or timing separation (e.g., 4 hours) or absorption reduction guidance.
Taking Vascepa with colestipol may decrease Vascepa absorption.
The provided label text does not mention colestipol or absorption reduction guidance.
VASCEPA may increase the risk of bleeding when taken with oral anticoagulants or antiplatelet agents (as a general statement).
While general monitoring with anticoagulants/antiplatelet agents for bleeding is supported, the provided label text does not explicitly provide this phrasing as a blanket interaction statement for 'oral anticoagulants' specifically beyond 'concomitant anticoagulants and/or antiplatelet agents.'
VASCEPA may increase the risk of hypotension when taken with antihypertensive medications.
The provided label text does not support hypotension/antihypertensive interaction claims.
Taking Vascepa with other medications may require consulting a doctor before combining them.
The provided label text does not include this generalized counseling statement.
Contradictions
High
AI Statement
VASCEPA reduces the risk of pancreatitis in patients with severe hypertriglyceridemia.
Label Reference
Label 1 INDICATIONS AND USAGE > Limitations of Use: 'The effect of VASCEPA on the risk for pancreatitis in patients with severe hypertriglyceridemia has not been determined.'
Important Omissions
For the cardiovascular risk-reduction indication, label details the required TG threshold (≥150 mg/dL) and the specific patient risk categories; these details are not verified within the user's claim list beyond partial alignment, and the label's 'Limitations of Use' about pancreatitis should be treated as material when discussing triglyceride-related outcomes.
Importance:
Moderate
Safety Assessment
Potential Patient Risk:
Moderate
A contradiction exists regarding pancreatitis risk reduction in severe hypertriglyceridemia (label states effect has not been determined). Several other claims (e.g., statin muscle damage, NSAID bleeding, INR monitoring, cholestyramine timing) are unsupported by the provided label text, which could lead to inaccurate expectations or practices.
Regulatory Assessment
| On Label |
No |
| Off-label Discussion |
No |
| Promotes Unapproved Use |
No |
| Hallucination Risk |
Moderate |
Recommendation
Partially Aligned
Primary Issue
Unsupported/incorrect interaction and monitoring claims; and a direct contradiction regarding pancreatitis risk reduction.
Suggested Improvement
Limit claims to those explicitly supported by the provided label text (indications; increased bleeding risk/monitoring with anticoagulants and/or antiplatelet agents; avoid stating pancreatitis risk reduction and avoid asserting specific drug-specific interactions (e.g., warfarin INR adjustments, statin muscle damage, NSAID bleeding, cholestyramine timing) that are not present in the supplied excerpts).